Publicacions en col·laboració amb investigadors/es de Centro Nacional de Investigaciones Cardiovasculares Carlos III (9)

2023

  1. Circulating ST2, from biomarker to pathogenic mediator

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 672-674

  2. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis

    Molecular Therapy - Nucleic Acids, Vol. 32, pp. 704-720

2022

  1. Critical warm ischemia time point for cardiac donation after circulatory death

    American Journal of Transplantation, Vol. 22, Núm. 5, pp. 1321-1328

2021

  1. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction

    Journal of the American College of Cardiology, Vol. 77, Núm. 14, pp. 1747-1759

  2. The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status (Scientific Reports, (2020), 10, 1, (13553), 10.1038/s41598-020-70454-8)

    Scientific Reports

  2. Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure

    Journal of the American College of Cardiology, Vol. 73, Núm. 9, pp. 1016-1025

2018

  1. Pulmonary Production of Soluble ST2 in Heart Failure

    Circulation. Heart failure, Vol. 11, Núm. 12, pp. e005488